NFKB1 and acute myeloid leukemia: NF-κB activity is aberrantly increased in primitive human leukemia cells compared to normal primitive bone marrow cells [47, 77, 115, 116], thus it provides a novel concept to treat AML by targeting the difference between HSCs and LSCs as exemplified by the different NF-κB activity between them.